Evidence map›Paper›PMID 28915659›Full record

ArticleOncotarget2017

Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity.

Ruth Dannenfelser, Marianne Nome, Andliena Tahiri, Josie Ursini-Siegel, Hans Kristian Moen Vollan, Vilde D Haakensen, Åslaug Helland, Bjørn Naume, Carlos Caldas, Anne-Lise Børresen-Dale and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. RUNX1-deficiency drives immune-active ERbioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Breast cancer resistance mechanisms: challenges to immunotherapy.Breast cancer research and treatment · 2021
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Ruth DannenfelserDepartment of Computer Science, Princeton University, Princeton, New Jersey, United States of America.
Marianne NomeInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Andliena TahiriInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Josie Ursini-SiegelLady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada.
Hans Kristian Moen VollanDepartment of Clinical Molecular Oncology, Division of Medicine, Akershus University Hospital, Ahus, Norway.
Vilde D HaakensenDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Åslaug HellandDepartment of Oncology, Division for Surgery, Cancer, and Transplantation, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Bjørn NaumeDepartment of Oncology, Division for Surgery, Cancer, and Transplantation, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Carlos CaldasCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Anne-Lise Børresen-DaleDepartment of Clinical Molecular Oncology, Division of Medicine, Akershus University Hospital, Ahus, Norway.
Vessela N KristensenInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Olga G TroyanskayaDepartment of Computer Science, Princeton University, Princeton, New Jersey, United States of America.
Oslo University Hospital · NOAkershus University Hospital · NOPrinceton University · USUniversity of Oslo · NOMcGill University · CAUniversity of Cambridge · GB

Funding

lntegration and Visualization of Diverse Biological DataR01GM071966 · NIGMS · PRINCETON UNIVERSITY · PI TROYANSKAYA, OLGA G · 2005 to 2022
$6.4M
Cancer Research UK 16465Cancer Research UK 16942Medical Research Council MR/M008975/1Medical Research Council MR/P012442/1NIGMS NIH HHS R01 GM071966
6 · The paper itself

Abstract

The tumor microenvironment is now widely recognized for its role in tumor progression, treatment response, and clinical outcome. The intratumoral immunological landscape, in particular, has been shown to exert both pro-tumorigenic and anti-tumorigenic effects. Identifying immunologically active or silent tumors may be an important indication for administration of therapy, and detecting early infiltration patterns may uncover factors that contribute to early risk. Thus far, direct detailed studies of the cell composition of tumor infiltration have been limited; with some studies giving approximate quantifications using immunohistochemistry and other small studies obtaining detailed measurements by isolating cells from excised tumors and sorting them using flow cytometry. Herein we utilize a machine learning based approach to identify lymphocyte markers with which we can quantify the presence of B cells, cytotoxic T-lymphocytes, T-helper 1, and T-helper 2 cells in any gene expression data set and apply it to studies of breast tissue. By leveraging over 2,100 samples from existing large scale studies, we are able to find an inherent cell heterogeneity in clinically characterized immune infiltrates, a strong link between estrogen receptor activity and infiltration in normal and tumor tissues, changes with genomic complexity, and identify characteristic differences in lymphocyte expression among molecular groupings. With our extendable methodology for capturing cell type specific signal we systematically studied immune infiltration in breast cancer, finding an inverse correlation between beneficial lymphocyte infiltration and estrogen receptor activity in normal breast tissue and reduced infiltration in estrogen receptor negative tumors with high genomic complexity.

Indexed as

breast cancerimmune infiltrationimmune profilinglymphocyte infiltrationnormal breast tissue

Identifiers

PMID28915659
PMCPMC5593630
OpenAlexW2731917842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.